# Independent reporting-standard and journal-readiness review

Review date: 8 November 2026. Reviewer role: reporting standards, provenance, and submission declarations. Evidence inspected: the current `manuscript/manuscript.md`, `manuscript/README.md`, `docs/novelty_evidence_report_2026_10_31.md`, `docs/research_protocol.md`, and the aggregate split-coverage record. This is an AI-assisted internal review, not independent human peer review, ethical approval, or a validated quality-score instrument.

## Overall decision

The existing manuscript can support a carefully bounded **exploratory retrospective comparison**. It is not ready to submit as a confirmatory model-validation study or clinical decision-support system. Its strongest reporting features are explicit input contracts, participant-level partitions, correction and exclusion disclosure, and appropriately conditional uncertainty statements. Its weakest sections are the literature narrative, cohort characterization, declaration completeness, and the distinction between the original clinical study and the present release-derived analysis.

A strong journal manuscript should report what was actually done and acknowledge unavailable evidence. Writing cannot supply unperformed alert analyses, population characterization, ethics determinations, independent external graph validation, or model-fit uncertainty. These are different kinds of gaps and should be listed separately. There is no universal checklist that guarantees acceptance by a “top-tier” journal, and external validation is not automatically a requirement for every exploratory methods paper. It becomes necessary for an external-generalization claim; prospective evidence is necessary for a prospective-benefit claim.

## Primary reporting sources and intended use

- **TRIPOD+AI** is the primary reporting framework for this model-development/comparison manuscript. The official site describes its scope across regression and machine-learning prediction models and supplies the 27-item checklist, expanded explanations, and a separate abstract checklist. Use it to locate reporting omissions, not to certify methodological validity. [Official TRIPOD site](https://www.tripod-statement.org/); [official checklist, version 11 January 2024](https://www.tripod-statement.org/wp-content/uploads/2019/12/TRIPODAI_checklist.pdf); [expanded checklist](https://www.tripod-statement.org/wp-content/uploads/2024/04/TRIPODAI-Supplement.pdf); [abstract checklist](https://www.tripod-statement.org/wp-content/uploads/2019/12/TRIPODAI-for-Abstracts.pdf); [primary statement](https://doi.org/10.1136/bmj-2023-078378).
- **PROBAST+AI** addresses model-development quality and evaluation risk of bias separately, across participants/data sources, predictors, outcome, and analysis. It includes 16 development and 18 evaluation signalling questions, with applicability assessments. This review uses its structure for a preliminary concern map; it is not a completed independently adjudicated PROBAST+AI assessment. [Primary paper](https://doi.org/10.1136/bmj-2024-082505); [primary indexed record](https://pubmed.ncbi.nlm.nih.gov/40127903/); [primary full text](https://pmc.ncbi.nlm.nih.gov/articles/PMC11931409/).
- **STROBE** provides an adjunct for the observational cohort description. Its cohort checklist is useful for setting, eligibility, participant flow, missingness, and generalizability. It does not replace prediction-model reporting. [Official checklist collection](https://www.strobe-statement.org/checklists/); [official cohort checklist](https://www.strobe-statement.org/download/strobe-checklist-cohort-studies-pdf).
- **ICMJE** governs authorship, disclosures, and responsibility. Human authors remain responsible for AI-assisted content; AI tools cannot be authors. Writing assistance belongs in acknowledgments, and substantive AI use for analysis should be disclosed in Methods as well as submission materials. [Official AI use by authors](https://www.icmje.org/recommendations/browse/artificial-intelligence/ai-use-by-authors.html); [official authorship and contributions guidance](https://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html); [January 2026 recommendations](https://www.icmje.org/icmje-recommendations.pdf).

No journal has been selected. Consequently journal-specific word limits, reference limits, article type, figure/table limits, required patient-involvement format, structured abstract headings, and AI policy remain decisions for the authors rather than verified compliance claims.

## Rating scale and initial section ratings

Scores are editorial judgments about this inspected draft, using the same anchored five-point scale: **1** = absent or materially misleading; **2** = substantial omissions or difficult to use; **3** = useful working draft with material revisions; **4** = strong reporting with bounded remaining gaps; **5** = polished and fully evidenced within the stated study scope. Decimal scores denote intermediate judgments. Scores do not measure clinical validity, predict acceptance, or replace checklist evidence.

| Part | Initial score /5 | Reason and required improvement |
|---|---:|---|
| Title | 4.5 | Names population, outcome, and retrospective development design; retain the development qualifier and avoid clinical KG/explainability promises. |
| Abstract | 3.5 | Contains quantitative results and conditional intervals, but is dense, gives insufficient setting information, and devotes conclusion space to an external CGM diagnostic not described in abstract methods. Center the aligned-control question; mention late-fusion comparison secondarily. |
| Introduction and contribution | 2.0 | Extensive relevant prior art is compressed into one very long paragraph. Replace with 4–6 coherent paragraphs and move the source-by-source novelty defense to a supplement. |
| Cohort and data provenance | 3.5 | Clear release counts and reserved-group distinction; original study setting/dates and released analytic date spans are not adequately resolved; demographic characteristics are absent. |
| Outcome, predictor, missingness definitions | 4.0 | Strong operational definitions and explicit occurrence-time assumptions. Outcome/predictor availability and demographic measurement consistency are unverified. |
| Model and training descriptions | 4.0 | Architecture widths, count matching, token features and optimizer are unusually explicit. Ensure the primary two-epoch aligned-control settings are not left implicit from the earlier one-epoch comparison. |
| Statistical analysis | 4.0 | Participant units, AP denominator, fixed-fit intervals and source inconsistencies are explicit. Add sample-size rationale, the exact cross-seed estimand and resampling description; avoid generic confidence language. |
| Results | 4.0 | Source-linked tables are useful; emphasize the stricter aligned comparison first. Add conventional cohort/data-characteristics presentation with measured and unavailable fields clearly distinguished. |
| Discussion | 3.5 | Scientifically cautious, but repetitive; lead with comparator dependence and distinguish optimization uncertainty from graph-semantic claims. |
| Limitations | 4.5 | Many material limitations are openly stated; consolidate repeated text and prioritize the threats that limit inference most. |
| Ethics and author declarations | 1.5 | Visible placeholders correctly avoid invention, but approval/exemption, authorship, funding, interests, PPI and data/code release terms remain unavailable. These are hard submission blockers. |
| Reproducibility/document navigation | 3.5 | Evidence map and generation script are valuable; README has stale PDF/build statements, public code/environment/archive details remain missing, and old documents can be mistaken for current executed methods. |
| Submission readiness | 2.5 | A credible development manuscript can be revised, but missing author facts, source characterization, and a chosen journal prevent an honest “submission-ready” designation. |

## Full TRIPOD+AI item/subitem location ledger

This is an original compliance crosswalk, **not a reproduction of the checklist**. Short labels identify official item IDs; consult the linked official checklist for complete requirements. Status refers to the pre-revision manuscript inspected for this review. **Met** means the relevant reporting is present for this retrospective scope; **Partial** means some evidence or text is missing; **Missing** means no adequate report was located; **N/A** applies only to the stated analysis and is justified explicitly. No overall percentage is calculated because reporting presence and study quality are different constructs.

| Item | Short label | Status | Current location and action |
|---|---|---|---|
| 1 | Title | Met | Title identifies a retrospective development study, T1D and hypoglycemia prediction. |
| 2 | Abstract | Partial | Abstract contains model inputs, endpoint, size and contrasts. Add setting and registration status; simplify comparator hierarchy and remove unsupported clinical implications. |
| 3a | Rationale | Met | Introduction explains CGM risk prediction and context records; cite the closest controls without claiming field-wide absence. |
| 3b | Intended context | Partial | T1D/Loop is identified. State that intended current use is an offline research benchmark, with researchers as users; no deployment action or selected clinical decision rule exists. |
| 3c | Inequalities | Missing | No source-grounded account of selection/access differences in the intended population. Add a brief supported limitation; do not assign the original study's demographic composition to the analytic cohort. |
| 4 | Objectives | Met | Introduction states comparison, alignment and routing questions. Put the stricter aligned comparison first in the revised hierarchy. |
| 5a | Data sources | Partial | Methods 2.1 identifies public Loop release; explain source representativeness and separate DCLP CGM diagnostic data. |
| 5b | Dates | Missing | Release date is reported, but release-derived accrual/follow-up date ranges are not established. Original published-study dates can be supplied as context only. |
| 6a | Setting | Partial | Outpatient/real-world context is implicit. Describe original study as U.S., outside clinic, decentralized; do not invent clinic-center counts for the release-derived population. |
| 6b | Eligibility | Met | Methods 2.1–2.3 and Results 3.1 give participant modality presence and per-window criteria. Add a consolidated flow diagram. |
| 6c | Treatment | Partial | Loop/AID and basal/bolus features are described. The delivered treatment process during the future outcome window is not modeled causally; state this. |
| 7 | Preparation | Partial | Methods 2.2–2.4 specify deduplication, conflict handling, grid tolerance, masks and tokenization. Processing consistency across demographic groups has not been assessed. |
| 8a | Outcome | Met | Methods 2.3 defines any observed future CGM below70, complete future, 30 minutes, strict boundary. Include rationale and automated measurement limitations. |
| 8b | Outcome assessors | N/A | Automated source-CGM threshold label; no subjective outcome adjudicator was used. Explicitly state this. |
| 8c | Outcome blinding | Partial | Automated construction and no future CGM predictors reduce subjective leakage. Document programmatic temporal separation; do not call it blinded clinical adjudication. |
| 9a | Predictor choice | Partial | Methods 2.4 describes retained modalities and normal-bolus rules. Explain availability-driven choice and preprocessing choices informed by development inspection. |
| 9b | Predictor definitions | Met | Methods 2.3–2.4 defines windows, units, masks, subtype hashing, age/scaling, unknown values and occurrence-time policy. |
| 9c | Predictor assessors | Partial | No manual adjudicator was used for this pipeline, but food records originate from user entry. Distinguish source reporting from algorithmic extraction; no independent validity assessment is established. |
| 10 | Study size | Missing | Numbers are reported, but no available-data rationale or calculation is stated. Report all eligible release data, no prospective power calculation if confirmed, and participant rather than window independence. |
| 11 | Missingness | Partial | Unknown future labels, history masks, unknown event values and no-record interpretation are explicit. Add variable/cohort missingness table and observation-selection limits. |
| 12a | Data partitioning | Met | Methods 2.5/Table1: mutually exclusive participants within configurations, overlapping training groups, exploratory reuse. Retain the distinction from untouched nested CV. |
| 12b | Transformations | Met | Methods 2.4 gives fixed scaling divisors and hash buckets; no patient-derived fitted scaling is implied. |
| 12c | Model building | Partial | Methods 2.6–2.9 contain architectures and fixed schedules. Add a planned-versus-executed decision register and explicit selection history. |
| 12d | Cluster variation | Partial | Participant bootstrap and per-fold/seed reporting are present. No sites/countries analysis or demographic heterogeneity is available; report that limit. |
| 12e | Metrics | Partial | Methods 2.10 defines AP/Brier. Calibration plots, utility, lead-time and alert burden are unperformed; state these as unassessed rather than describe Brier as calibration proof. |
| 12f | Updating methods | N/A | No reported model updating/recalibration in the graph comparison; DCLP frozen CGM replay has no refit. |
| 12g | Evaluation inference | Partial | Architecture and checkpoint/source identity are described, but a publicly accessible runnable code/object/environment release remains pending. |
| 13 | Imbalance | Met | Methods 2.9 uses unweighted BCE and natural validation prevalence. Explicitly state no resampling/reweighting in the main comparisons. |
| 14 | Fairness | Missing | No fairness mitigation or subgroup performance analysis. A clear “not assessed” statement is required; algorithmic fairness cannot be inferred from participant disjointness. |
| 15 | Output | Met | Risk logit converted to probability and evaluated by ranking/probabilistic error; no selected alert threshold. Make lack of deployment operating point explicit. |
| 16 | Development/evaluation differences | Partial | Same-release participant partitioning is described. DCLP use needs a separate population/task/clock/input comparison table if retained in the main article. |
| 17 | Ethics | Missing | Declarations hold an author placeholder for this secondary analysis. Original Jaeb approval does not establish local approval/exemption. |
| 18a | Funding | Missing | Authors must confirm funding and funder role; do not insert an unverified no-funding statement. |
| 18b | Interests | Missing | Each human author must provide a declaration. |
| 18c | Protocol | Partial | Historical protocol exists but is not clearly linked with an executed-methods/deviation register in the manuscript. |
| 18d | Registration | Missing | No identifier or explicit unregistered statement is reported for the secondary analysis. Original NCT03838900 is not its registration. |
| 18e | Data access | Partial | Custodian and protected artifacts stated. Exact reuse terms and access route need author/custodian confirmation. |
| 18f | Code access | Partial | Repository scripts exist; actual public URL, archive/version, environment and license remain unverified. |
| 19 | Patient/public involvement | Missing | Placeholder. Original study participant involvement is not evidence of involvement in this secondary analysis. |
| 20a | Participant flow | Partial | Roster919→CGM851→multimodal835→development652/reserved183 is described. Participant outcome-positive and observation-time summaries need a consolidated table; positive windows are not episode counts. |
| 20b | Characteristics | Missing | No release-derived age/sex/race/therapy/device table or monitoring-duration summary is verified in the current manuscript; distinguish unavailable from absent in source release. |
| 20c | Evaluation distributions | Partial | Fold counts and prevalence available; demographic/predictor distribution comparison and external-data contrast incomplete. |
| 21 | Analysis denominators | Met | Table1 and Results3.1 specify validation people, windows, positives, and AP650/Brier652 denominator. Add train-side windows/positives to supplement if available. |
| 22 | Full specification | Partial | Layer widths and transformations give substantial detail. Code/environment and an accessible frozen inference object or rebuilding route are still needed for third-party prediction. |
| 23a | Performance | Partial | Paired point estimates/intervals given and appropriately conditional. Subgroup analyses, calibration/alert curves and adequate tuning uncertainty are unavailable; no universal low-bias certification. |
| 23b | Heterogeneity results | Partial | Fold and seed contrasts presented; no independent site/cohort estimates for graph models. |
| 24 | Updating results | N/A | No updated graph model or recalibration is reported. |
| 25 | Interpretation | Met | Discussion acknowledges comparator dependence, fixed-fit uncertainty, development reuse and current negative aligned-control finding. Add fairness/access context. |
| 26 | Limitations | Met | Substantial limitations are explicit. Prioritize model selection, short schedules, data completeness/availability, cohort selection and transfer limits. |
| 27a | Input-quality use | Partial | Offline handling is specified. No clinically validated implementation pathway; state deployment input-quality rules have not been evaluated. |
| 27b | User interaction | Partial | No clinical workflow/user study. Define present users as researchers; training/support for patients or clinicians is unstudied. |
| 27c | Further research | Met | Discussion/research reports list convergence, delayed availability, independent explanation, external event-model and holdout gates. |

## Abstract-specific audit

All 13 official abstract items are considered. Items **1** (title), **2** (rationale), **3** (objective), **4** (source), **6** (outcome/horizon), **7** (model/validation), **8** (metrics), **9** (people/outcomes), **10** (predictors), **11** (estimates/intervals), and **12** (interpretation) are substantially present, though compression and comparator hierarchy need improvement. Item **5** (setting/eligibility) is partial; item **13** (registration) is missing. Numbers labeled as positive windows must remain so labeled rather than becoming independent hypoglycemia events. The source for these identifiers is the [official abstract checklist](https://www.tripod-statement.org/wp-content/uploads/2019/12/TRIPODAI-for-Abstracts.pdf).

## Preliminary PROBAST+AI concern map

This is a scoped internal appraisal; a formal tool completion requires all signalling questions and justified domain judgments by qualified human assessors. The clinical target for this appraisal is **generalization of a hypoglycemia predictor to new people with T1D in real-time use**. Risks are lower for the narrower task of reproducing the saved retrospective model contrasts, which is an artifact-integrity question rather than clinical validation.

| Domain | Main evidence | Development/evaluation concern | Applicability concern |
|---|---|---|---|
| Participants and data sources | Convenience/technology-engaged source population; modality-presence and complete-future selection; analytic demographics unavailable | Selection can favor well-recorded periods and participants; subgroup completeness unassessed | Broader T1D populations, MDI users, lower-resource settings, and other devices are unverified |
| Predictors | Definitions common across arms; source event times known; usable arrival times not established | Occurrence-time replay assumes immediate access; source food/basal/bolus semantics imperfect | Real-time availability differs from the evaluated input policy |
| Outcome | Automated future-CGM threshold, complete six-slot outcome mask | Strong repeatability for the release-local endpoint; no sustained-event or symptom adjudication | A future sensor threshold is not severe/symptomatic hypoglycemia or demonstrated useful warning |
| Analysis | Participant separation within fits; shared windows; two fixed seeds; repeated development inspection; limited schedules | Outcome-guided model selection, optimization uncertainty and unmodeled fit variability limit performance inference | No reserved-performance evaluation, externally evaluated graph, calibration/alert analysis, or deployment operating point |

A green hash/CRC/metadata audit does not reduce these methodological concerns by itself. Conversely, openly reporting an unperformed analysis is adequate transparency but does not mean that analysis has been completed.

## Original Loop study context verified from primary source

Lum et al.'s original published cohort included **558 new Loop users**, with U.S.-resident adults and children studied outside clinics. Enrollment ran January–August2019 and the reported data collection ended April2020, allowing six months of follow-up. The original study had Jaeb IRB approval and electronic consent, with registration NCT03838900. These facts describe the original published cohort; they cannot be assigned as the exact dates, characteristics, approval, or registration of the release-derived roster919/current analytic835/development652. The released analytic date spans and demographic table need their own audit. [Original primary full text, Methods](https://journals.sagepub.com/doi/full/10.1089/dia.2020.0535).

The source article's reported race, income, insurance and age distribution must not be copied into a table labeled as the present652-person analytic population. A context sentence may note original-study selection and describe the current table as unavailable pending release audit.

## Prioritized revision actions

### A. Text and document fixes that can be completed now

1. Restructure the introduction into a short clinical rationale, closest predictive/event-graph precedents, unresolved comparison question, and current contribution. Move exhaustive prior-art comparisons into supplementary tables.
2. Center the title/abstract/results hierarchy on graph versus time-aligned pooling. State fixed schedules and exploratory reuse; preserve historical graph-versus-sequence results as supporting evidence.
3. Add a single study-population diagram with source roster, canonical CGM population, modality intersection, development/reserved groups, and per-window eligibility. Label exclusions where counts are genuinely known; do not invent reasons for all68 source-roster members without CGM.
4. Add an available-data sample-size statement, a study registration statement, explicit current research-only use, and transparent fairness/non-assessment text after confirming the record.
5. Add an executed-methods register linking the historical protocol and its deviations: filling option replaced by masks, one-second logical-grid policy, event cap selected from development, comparator changes, inspected development outcomes, source mismatch exclusion/rerun, and correction of AP handling.
6. Move substantive AI-assisted analysis to Methods and retain writing assistance in acknowledgments. Human authors must approve its factual description and comply with the chosen journal policy.
7. Correct stale README assertions: Tectonic and the rebuilt PDF are present in current workspace. Distinguish compilation/format verification from clinical/statistical validity.
8. Add completed versus unperformed analysis tables, source-linked result maps, and a documented software/runtime environment rather than imply that every historical prototype was part of one frozen primary comparison.

### B. Author-dependent hard submission blockers

Human author list/order/affiliations and responsibility; secondary-analysis ethics review/exemption and consent basis; actual funding/funder role; competing interests; contribution roles; patient/public involvement; data reuse/redistribution terms; target journal/article type; public code archive/license/environment; final sign-off on source citations and AI use. Existing placeholders must remain explicit until these facts are supplied.

### C. Empirical work needed for stronger claims

Replicated optimization and tuning uncertainty; strong CGM-only matched baseline; replicated same-schedule event-disabled and relation controls; calibrated operating-point and chronological episode-alert analyses; delayed-availability assessment; release-derived demographic characterization and subgroup performance; independent explanation tests; protected holdout evaluation after final protocol freeze; harmonized external event/graph validation. The current development paper can report these as absent, but cannot claim the clinical findings they would establish.

## Completion condition for this internal review

The document/reporting revision is satisfactory when each applicable item has a manuscript/supplement location or an explicit evidence gap; the revised sections receive a second review on the same scale; the rendered manuscript contains current tables/references; and the author-dependent and empirical gaps remain visible. A high writing score cannot convert an exploratory study into confirmatory or clinical evidence.

## Second review of the revised dossier — 8 November 2026

I independently reread the regenerated `manuscript.md`, `supplementary_methods.md`, `submission_readiness_2026_11_08.md`, `README.md`, and the initial sections of `docs/research_master_record_2026_11_08.md`. This review judges the revised reporting against the same scale and standards above. It does not convert the current research into a registered or confirmatory study and does not certify target-journal acceptance.

### Before and after editorial ratings

| Part | Before /5 | Revised /5 | Verified improvement or continuing limit |
|---|---:|---:|---|
| Title | 4.5 | 4.5 | Now names both graph and time-aligned pooling and identifies exploratory participant-disjoint scope. |
| Abstract | 3.5 | 4.4 | Clearer question and comparator hierarchy; quantitative contrast and fixed-fit uncertainty remain explicit. Setting/eligibility can be compressed more precisely; final journal abstract format remains unselected. |
| Introduction and contribution | 2.0 | 4.5 | Five coherent paragraphs replace the oversized literature paragraph; closest task/graph precedents retained; exhaustive defense moved to evidence materials. |
| Cohort and data provenance | 3.5 | 4.0 | Original U.S./outside-clinic setting and dates are distinguished from release-derived groups; sample derivation and unavailable characterization are explicit. Analytic demographic/date/monitoring summaries still missing. |
| Outcome, predictor, missingness definitions | 4.0 | 4.6 | Automated labels, recorded treatment process, incomplete-future exclusion, non-low eligibility, masks, unknown events and availability assumptions are well defined. |
| Model and training descriptions | 4.0 | 4.6 | Supplement now gives full module counts, pooling gates/gains and CGM-path differences, revealing that this is not an isolated graph deletion. Fixed budgets and development reuse are clear. |
| Statistical analysis | 4.0 | 4.5 | Adds available-data rationale, exact within-person cross-seed estimand, percentile resampling and no-equivalence statement. Model-fit/tuning uncertainty remains genuinely unestimated. |
| Results | 4.0 | 4.5 | Aligned comparison is foregrounded; cohort-flow figure added and outcome windows distinguished from episodes. Cross-references need one final consistency pass after table reordering. |
| Discussion | 3.5 | 4.4 | Implementation and optimization differences prevent causal graph-message claims; clinical interpretation remains appropriately bounded. |
| Limitations | 4.5 | 4.6 | Fairness, selection, missing data, timing and external-validation limits are explicit and tied to interpretation. |
| Ethics and author declarations | 1.5 | 2.0 | Missing facts are organized into an actionable author ledger and not fabricated. The declarations themselves remain incomplete. |
| Reproducibility/document navigation | 3.5 | 4.3 | Master record, source inventory, supplement and review/response navigation are clear; stale PDF/Tectonic statements are corrected; missing raw basal files and mutable source histories are disclosed. Public code archive/environment/license remain pending. |
| Submission readiness | 2.5 | 3.0 | Current state is clearer and more defensible. Author/ethics/data-use/journal decisions and cohort characterization prevent a submission-ready certification. |

The revised **writing and reporting** are substantially stronger. The lower declarations/readiness ratings are not evidence that prose needs embellishment; they represent absent human decisions and empirical evidence. No amount of automated editing can honestly raise those items to5/5 without their underlying facts.

### TRIPOD+AI status changes after revision

Every item in the initial full ledger remains in scope. The following are updates; items not listed retain their original disposition.

| Item(s) | Revised reporting disposition | Evidence in revised files |
|---|---|---|
| 2 / abstract | Stronger partial | Abstract centers aligned pooling and discloses development selection; source setting remains limited and no current registration identifier is available. |
| 3b | Met for present research use | Introduction states retrospective comparative research output; supplement/readiness distinguish from a clinical decision rule. |
| 3c | Partial | Selection/fairness limitations now explicit. A source-grounded inequality discussion and analytic subgroup characterization remain unavailable. |
| 5a | Met for development source description | Methods2.1 identifies release, original study context, and difference between558 and919/835/652; DCLP diagnostic scope separately bounded. |
| 5b | Partial | Original-study accrual/follow-up dates supplied with correct denominator. Current released analytic observation bounds remain unresolved. |
| 6a | Met for source context | Methods2.1 identifies decentralized U.S. outside-clinic original setting without inventing site counts for the current analysis. |
| 6c | Met for bounded treatment reporting | Methods2.3 states outcomes occur under recorded treatment process; untreated risk and intervention effect are not estimated. |
| 8a–c | Met / N/A / met for algorithmic construction | Outcome is explicitly automated, without subjective adjudication; supplementS1 states future measurements define labels/coverage rather than predictors. Clinical blinding is not claimed. |
| 9a | Partial | Availability-driven modality selection and development-informed transformations are explained; a full prospective predictor-selection procedure was not performed. |
| 10 | Met for available-data exploratory rationale | Methods2.1 and supplementS1 state available eligible data and no a priori power calculation. They do not claim clinical power from millions of windows or establish precision of a final model. |
| 11 | Stronger partial | S1/S2 table identifies observed masks, incomplete outcomes and unknown values. Demographic missingness, monitoring duration and excluded-data distribution remain unavailable. |
| 12c | Met for reporting executed development | Planned-versus-executed register and historical protocol links document changes; no unperformed nested validation is implied. |
| 12e | Met for scoped outcomes; performance breadth remains incomplete | Metrics and their limits are explicit; calibration/alert/utility analyses are listed as unperformed. This is reporting transparency, not their completion. |
| 14 | Partial, explicit non-assessment | Methods2.1, limitations and readiness ledger identify demographic fairness/subgroup estimates as unassessed. No fairness claim follows. |
| 18c | Met | SupplementS6 and master record connect protocol, development decisions, corrections and executed methods. |
| 18d | Partial | Methods2.10 states no prospective registration identifier is available and local run plans are not registration. Authors must confirm a definitive registered/unregistered statement before submission. |
| 20a | Stronger partial | Figure1 and source/analysis flow are clear, but follow-up/monitoring-time summaries are still unavailable. |
| 20b–c | Partial | S1 transparently lists characterization/distribution gaps; no demographic table can be manufactured from original-source percentages. |
| 22 | Stronger partial | S3 supplies reproducible architecture/transform definitions and source-code paths. Public immutable archive, environment and model rebuilding/inference release remain author tasks. |
| 27a–b | Met for offline research scope; clinical scope unassessed | Research-only input handling and source/availability checks are described. No patient/clinician workflow or deployment training is evaluated. |

The author-dependent items17,18a,18b,18e,18f and19 still require actual confirmations and/or release artifacts. The update should not be reported as100% TRIPOD+AI compliance. Item completeness is also not a risk-of-bias score.

### Fixable consistency findings sent to the lead reviser

1. Methods2.10 currently says “graph-versus-sequence or graph-versus-pooling” but ends the interval definition “graph minus sequence.” Use “graph minus its comparator” so the analysis description covers both contrasts.
2. Results3.2 still cites “Tables4 and5” although reordered pooling tables are labeled2 and3. Scan every textual table/figure cross-reference after numbering.
3. Some supplementary/master prose joins numbers to words, for example “with18.0182,” “the835,” and “at most64.” These are editorial spacing errors, not substantive findings, and should be cleaned before final rendering.
4. The abstract could identify the source outpatient/AID setting with a few words if the chosen journal word budget allows; never imply exact analytic demographic attributes from the original558-person cohort.

These were reported while the lead reviser was still working; a final machine/link/render audit should verify their resolution rather than assume it from this review.

## Target-format decision: JAMIA Research and Applications

The authors have now supplied names/order: **Pronab Chandra Roy; Lihui Liu**. Affiliations and other author-specific declarations remain unconfirmed. Following the author's authorization to exercise judgment on format, the lead reviser selected **JAMIA, Research and Applications** as the working target. This is a format choice, not a finding that JAMIA will accept the study or that the work satisfies an unspecified “top-tier” threshold. The earlier statement that no journal had been selected describes the first-review snapshot.

The current [official JAMIA instructions](https://academic.oup.com/jamia/pages/General_Instructions), checked8November2026, provide these requirements:

| Requirement | Current official rule | Dossier action |
|---|---|---|
| Article label | Research and Applications | Use this exact category, rather than “Original Research.” |
| Length | Main text≤4000 words; abstract≤250 | Lead reviser is shortening main article; retain full methods/history in the supplement/master record. |
| Abstract headings | Objective; Materials and Methods; Results; Discussion; Conclusion | Use exact headings; separate Discussion from Conclusion. |
| Main structure | Include Background and Significance | Adapt the narrative section names. |
| Display limits | Tables≤4; figures≤6; references unlimited | Move additional fold/diagnostic detail to supplement. |
| Title page | ≤5keywords; complete author/contact details; word count | Use supplied name/order, retain missing affiliations/contacts as unresolved. |
| Files/layout | Double spacing; editable Word; PDF with LaTeX source permitted | Supply DOCX plus PDF/TeX, and editable tables. |
| Figures | Separate files; end legends; caption-linked alt text | Include labeled alt descriptions and export figure files. |
| Supplemental material | Online appendices may contain additional tables/figures/data/code | Cite supplements in the main article. |
| Data availability | Statement required; access information and dataset citation | Preserve third-party source terms and exact identifier limitations. |
| Authorship/disclosure | CRediT; AI use in cover letter and manuscript | Human authors confirm contributions and AI-use accuracy. |

The same official page excludes acknowledgments and references from its general length rule; its title-page count definition additionally excludes title page, abstract, figures and tables. For the final count, report the calculation explicitly and use a conservative main-text count including declaration/legend prose where the exceptions are ambiguous. A low enough main-text count avoids relying on an unsupported interpretation of exclusions.

The page recommends SI units. Clinical glucose thresholds can retain the familiar mg/dL expression with mmol/L equivalents at first mention; the source-unit conversion policy must remain unchanged. All reference, table and figure callouts must follow order of first citation. The page does not establish a blanket mandatory TRIPOD+AI checklist for this article type, so the manuscript should describe TRIPOD+AI as its adopted reporting framework, not invent a journal requirement.

### Reference eligibility nuance requiring editorial confirmation

The official instructions limit the reference list to published or in-press papers while also explaining website/electronic citations and permitting authors' own preprints. This does **not** establish how JAMIA will handle every thesis, conference proposal, and publicly available third-party preprint currently important to this novelty assessment. Preserve accurate publication status and the overlapping prior-art evidence; do not relabel a preprint peer-reviewed or remove an inconvenient source to strengthen novelty. Before submission, authors should resolve its allowable citation format or consult the editorial office. This is a format-policy uncertainty, not permission to suppress relevant evidence.

### Remaining target-format checks

After the shortened article is generated, verify actual main/abstract word counts, five exact abstract headings, no more than four main tables/six main figures, five or fewer keywords, sequential callouts, double-spaced DOCX, separate figure files, end legends and alt text, and the Data Availability Statement. Final title-page affiliations/contact information, ethics/consent, funding/interests, contribution roles, PPI, immutable code/archive/license and actual author approval remain required human facts. Formatting compliance cannot resolve the study's empirical limitations.

## Final target-format review of the shortened manuscript

This final pass inspected the generated JAMIA-format `manuscript.md`, the DOCX style XML, and generated LaTeX on8November2026. The author order is now Pronab Chandra Roy followed by Lihui Liu; the title page states that no institutional affiliations were declared. Actual corresponding-author contact details, author accountability/contribution approvals, ethics/consent basis and funding/interests/PPI facts remain unresolved.

### Measured format checks

The inspected copy has the exact five required abstract headings, a Background and Significance section plus Objective/Materials and Methods/Results/Discussion/Conclusion, five keywords, three main tables, two main figures, and two corresponding alt-text entries. Figure legends follow the references. DOCX defaults use `w:line="480"`, and LaTeX contains `\doublespacing`; these establish double-spaced body defaults, not a claim about final journal typesetting. The three tables remain editable Word tables.

For a reproducible independent count, I removed Markdown emphasis/headings and replaced Markdown hyperlinks with their visible labels. Whitespace-separated tokens gave **213 abstract words excluding heading labels** (220 including labels), **2,666 body words excluding Markdown table rows**, and **3,085 words when declarations and figure-legend/alt-text prose were conservatively added**. A separate lexical regular expression counted224 abstract words and3,201 conservative body/declaration/legend words. All variants were below the250/4000 target limits. These numbers describe the inspected copy before the final requested small abstract/spacing corrections; the final delivery audit should recount the actual packaged document after any edits. The reference list and title page were not counted as body text.

The excerpted abstract omitted the available positive-window count, even though TRIPOD+AI abstract item9 calls for outcome counts. I requested that the lead add1,296,297 **positive windows**, retaining the distinction from episodes. There is sufficient room below250 words to add complete-future/eligible-window wording as well. I also requested cleanup of joined words/numbers in figure alt text. Those are remaining editorial fixes, not missing analyses. The earlier comparator/interval wording and table-cross-reference errors have been corrected in the shortened body.

### Final section ratings for the bounded development paper

| Part | Initial /5 | Final reviewed /5 | Basis |
|---|---:|---:|---|
| Title | 4.5 | 4.6 | Specific comparator, population, endpoint and exploratory participant-disjoint scope. |
| Abstract | 3.5 | 4.4 | Clear five-heading argument and quantified main contrast; positive-window count and eligibility wording requested before final audit. |
| Background and contribution | 2.0 | 4.6 | Concise, source-grounded framing, established precedents, no first-in-field claim. |
| Cohort/provenance | 3.5 | 4.1 | Correct denominator distinctions, original-study context and missing analytic characterization clearly visible. |
| Outcome/predictors/missingness | 4.0 | 4.6 | Exact source-CGM target, complete-future selection, masks and retrospective time policy retained. |
| Models/training | 4.0 | 4.7 | Main paper is concise; supplement supplies explicit architecture/counts and identifies the control's CGM-path differences. |
| Statistical reporting | 4.0 | 4.6 | Participant unit, AP denominator, cross-seed estimand and fixed-fit uncertainty are explicit; unestimated fit/selection uncertainty is disclosed. |
| Results | 4.0 | 4.6 | Most stringent completed comparison leads; earlier studies are diagnostic context; tables/callouts are coherent. |
| Discussion/limitations | 3.5/4.5 | 4.6/4.7 | Clearly connects comparator dependence, changed CGM pathway, optimization limits and absent clinical evidence to the permissible interpretation. |
| Declarations | 1.5 | 2.0 | Author names supplied and missing facts organized; those facts remain unresolved and cannot be inferred from authorization to choose format. |
| Reproducibility/navigation | 3.5 | 4.4 | Master record, source inventory, supplementary contract, evidence map and source-file limitations support scrutiny; immutable public code/environment release pending. |
| Submission readiness | 2.5 | 3.0 | Target format is now concrete, but author facts, analytic characterization, reference-eligibility handling and complete public reproducibility still require resolution. |

No section receives5/5 because the documentation is still subject to author factual confirmation and final package/render inspection. These independent AI-assisted editorial scores indicate improvements in reporting, not a quantitative certification of methodological validity or journal acceptance. The strongest current inferential claim remains retrospective and implementation-specific. No new calibration, alert, fairness, optimization, clinical explanation or external event/graph validation was performed by this writing revision.

## Final factual and rendering addendum for package hashing

The user explicitly supplied the author order **Pronab Chandra Roy; Lihui Liu** and explicitly stated **no institutional affiliations**. The final title page reflects these supplied facts. References above to affiliations being unconfirmed concern earlier snapshots and are superseded by this addendum. Corresponding-author email/contact and acceptance of responsibilities, CRediT roles and author approvals, secondary-analysis ethics/consent basis, funding, competing interests, patient/public involvement, and data/code release declarations remain pending.

I verified that the current generated abstract now includes1,296,297 **positive windows**, eligible non-low indices, and complete future coverage. The earlier small abstract reporting omissions are resolved. The final delivery audit records232 abstract words and3,031 conservatively counted main-text words, with3 main tables,2 figures,5 keywords and32 main references; the independent whitespace count including abstract labels is232. These remain within the working JAMIA limits. The current generated LaTeX uses native `\linespread{1.667}` because the setspace package is unavailable, replacing the earlier `\doublespacing` implementation; the DOCX retains exact `w:line="480"` spacing. This rendering implementation change does not alter the evidence or manuscript interpretation.

No further substantive **fixable reporting defect** was identified in this final pass. Author-dependent facts and the documented empirical/generalizability gaps remain visible and prevent an unconditional submission-readiness claim. The final abstract reporting score is revised from4.4 to**4.6/5** after the positive-window and eligibility repairs; all other final section ratings above remain applicable. This review file is final for the delivery manifest/hash calculation.
